The machine in question is the CUL4-RING E3 ligase, or CRL4, a multi-component enzyme complex that normally serves as the cell’s quality-control apparatus. E3 ligases are the recognition modules of the ubiquitin-proteasome system: they bind specific target proteins and catalyze the attachment of ubiquitin chains, molecular tags that mark a protein for destruction by the proteasome. CRL4 accomplishes this through a scaffold protein called CUL4, a catalytic RING protein, and an adaptor known as DDB1, which in turn docks a substrate receptor that determines what gets destroyed. In uninfected cells, this system helps regulate DNA replication, DNA repair and other essential processes.

HIV-1 subverts this machinery with elegant economy. Rather than building its own degradation apparatus, the virus deploys Vpr, which binds to a cellular substrate receptor called VprBP, also known as DCAF1. Once Vpr docks onto VprBP, the viral protein acts as a mutable adaptor that can recruit a shifting cast of host proteins into the CRL4(VprBP) complex, delivering them to the catalytic core for ubiquitination and proteasomal degradation. Among the confirmed victims are restriction factors and regulators such as UNG2, a uracil-DNA glycosylase involved in DNA repair, and TET2, an enzyme that chemically modifies DNA. By degrading these factors, Vpr helps the virus counteract innate and intrinsic immune defenses and manipulate the cellular environment to favor replication.

What has puzzled structural biologists for years is how a single receptor-adaptor pair can accommodate substrates as chemically and structurally divergent as UNG2 and TET2. The new study addresses this question by determining cryo-electron microscopy structures of the DDB1-VprBP substrate recognition unit on its own and in complex with different Vpr-substrate assemblies. These structures capture the machinery in multiple conformational states, allowing the researchers to trace how the complex physically reorganizes itself to grip targets of different stoichiometries and dimensions.

The first key finding concerns the architecture of the receptor itself. VprBP is a large protein containing several domains, including a LisH domain and two Armadillo-like repeat domains, often abbreviated ARM-like domains, which form elongated, curved surfaces well suited to protein-protein interactions. The structures show that the LisH domain of VprBP is responsible for mediating dimerization of the DDB1-VprBP unit. This dimerization is not a trivial detail: it doubles the number of binding surfaces available and creates a symmetric platform on which two copies of a substrate can be engaged simultaneously. The LisH domain, a motif named for the Lis1 homology region where it was first characterized, has previously been implicated in oligomerization in other proteins, and this study confirms its structural role as the dimerization engine of the VprBP receptor unit.

The second and perhaps most striking discovery is the conformational plasticity of the ARM-like domains. In the structures, these domains are seen adopting two distinct orientations, which the authors describe as an up conformation and a down conformation. When the complex is bound to UNG2, a relatively small substrate, the two ARM-like domains in the up position wrap around and directly contact two symmetrically arranged UNG2 molecules, one on each side of the dimerized receptor unit. This arrangement effectively clamps the small substrate between the curved ARM-like surfaces, explaining how the complex achieves high-affinity recognition of a compact target.

When the researchers examined the complex bound to a larger fragment of TET2, however, the picture changed dramatically. The ARM-like domains swung into the down conformation, repositioning themselves to accommodate the bulkier substrate. This switch illustrates a structural principle that has emerged from studies of other multidomain receptors: conformational dynamics, rather than rigid lock-and-key binding, can allow a single scaffold to recognize chemically unrelated targets. In the case of VprBP, the up-to-down transition of the ARM-like domains appears to be the mechanical solution that lets the CRL4(VprBP) complex handle substrates ranging from compact enzymes to larger multi-domain proteins.

The implications for HIV biology are significant. Vpr’s ability to degrade diverse host factors is central to several aspects of viral pathogenesis, including the manipulation of the cell cycle, the modulation of DNA damage responses and the evasion of restriction factors. By showing exactly how Vpr-bound substrates are presented to the receptor, the new structures provide a mechanistic framework for understanding how the virus co-opts the host ubiquitin system. They also suggest that the flexibility of the ARM-like domains may be a general feature that permits Vpr, and possibly related viral proteins such as Vpx in HIV-2 and SIV, to recruit an evolving repertoire of substrates as the virus adapts to different host environments.

Beyond virology, the study has direct relevance to the booming field of targeted protein degradation. Pharmaceutical researchers have increasingly sought to repurpose E3 ligases as engines for degrading disease-causing proteins, designing bifunctional molecules that tether a target protein to an E3 ligase so that the cell destroys it. The CRL4(VprBP) system is particularly attractive for such efforts because Vpr demonstrates that the receptor can be induced to accept many different substrates. The new structures, by revealing the binding surfaces and conformational states that enable this promiscuity, could guide the structure-guided design of degraders that exploit VprBP to eliminate therapeutic targets, from oncogenic proteins to other disease drivers.

The work also underscores how much remains to be learned about the structural logic of viral hijacking. Each new structure of a hijacked E3 ligase reveals a different strategy: some viral proteins mimic natural substrate receptors, others insert themselves as adaptors, and still others remodel the receptor to change its specificity. The Vpr-VprBP system now stands as a textbook example of the adaptor strategy, with the added twist that the receptor itself is conformationally dynamic. As structural biologists continue to capture these machines in action, the boundary between viral manipulation and therapeutic engineering grows thinner, and the same molecular flexibility that HIV-1 exploits to evade immunity may one day be harnessed to treat human disease.

Subject of Research: Structural mechanism of substrate recruitment by the HIV-1 Vpr-hijacked CRL4(VprBP) E3 ubiquitin ligase

Article Title: Structural basis of diverse substrate recruitment by the HIV-1 Vpr-hijacked CRL4(VprBP) E3 ligase

Article References: Wang, D., Ding, W., Xu, J., Li, R., Cairoli, T., Liu, Q., Zhu, Y., & Xiang, Y. (2026). Structural basis of diverse substrate recruitment by the HIV-1 Vpr-hijacked CRL4(VprBP) E3 ligase. PLOS Pathogens, 22(10), e1014610. https://doi.org/10.1371/journal.ppat.1014610

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014610

Keywords: HIV-1, Vpr, VprBP, CRL4, E3 ligase, DDB1, UNG2, TET2, cryo-EM, protein degradation, ubiquitin-proteasome system, targeted protein degradation

To understand why this matters, it helps to picture the two signaling complexes that form after TNF binds its receptor, TNFR1. At the plasma membrane, TNFR1 recruits RIPK1 through its death domain to build complex I, a platform that activates the IKK/NF-κB and MAPK pathways and thereby promotes cell survival and inflammatory gene transcription. When complex I is destabilized, RIPK1 can instead nucleate cytosolic complexes: complex IIa, containing RIPK1, FADD and caspase 8, which drives apoptosis; or, when caspase 8 is inhibited, complex IIb, the RIPK1–RIPK3 necrosome that initiates necroptosis, a lytic form of cell death in which activated RIPK3 phosphorylates MLKL, sending it to the plasma membrane to rupture the cell. RIPK1 is a component of all these assemblies, but the biochemical event that converts it from a prosurvival scaffold in complex I into a prodeath kinase in complex II has remained elusive.

The search began with an unbiased genetic approach. The team, led by Haohao Lu and Tongde Du in the laboratory of Sudan He at the Suzhou Institute of Systems Medicine, together with She Chen and Henning Walczak, conducted a CRISPR–Cas9 screen in human HT-29 colon cancer cells using a guide RNA library targeting genes encoding ubiquitin E3 ligases, deubiquitinating enzymes and other ubiquitination-associated proteins. The cells were challenged with a necroptosis-inducing cocktail of TNF, a Smac mimetic and the pan-caspase inhibitor z-VAD, a combination known as TSZ. After four rounds of selection, the single guide RNA targeting HERC4 emerged as the most enriched hit among all the E3 ligases and deubiquitinases tested, marking the enzyme as a prime suspect in the cell death machinery.

Validation followed swiftly across cell types. HERC4-knockout lines generated in HT-29, LS 174T, THP-1 and Jurkat cells all showed marked resistance to necroptosis, surviving doses of TSZ that killed their wild-type counterparts. Reintroducing HERC4, even at subphysiological levels, restored sensitivity to the death stimulus. Crucially, the loss of HERC4 did not merely blunt a downstream effector: phosphorylation of RIPK1, RIPK3 and MLKL, the sequential activations that define the necroptosis pathway, were all significantly reduced in HERC4-deficient cells. MLKL oligomerization and its translocation to the plasma membrane, the final steps before necroptotic rupture, were likewise suppressed. The same protection appeared in mouse embryonic fibroblasts and in a second necroptosis model using a TAK1 inhibitor, establishing HERC4 as a driver acting upstream of the canonical RIPK1–RIPK3–MLKL axis in both human and mouse cells.

Because HERC4 is a ubiquitin ligase, the next question was which protein it decorates. Coexpression experiments showed that HERC4 increased polyubiquitination of RIPK1 but not of RIPK3. Using mutant ubiquitin restricted to single linkage types, the researchers found that HERC4 specifically catalyzes K63-linked chains, a modification classically associated with signal transduction rather than protein degradation, and indeed HERC4-mediated ubiquitination did not lead to RIPK1’s destruction. In vitro assays with recombinant proteins confirmed that HERC4 directly ubiquitinates RIPK1, and mapping experiments showed that the intermediate domain of RIPK1 binds the HECT domain of HERC4, the region that carries the ligase’s catalytic activity.

Mass spectrometry then pinpointed the exact modification site. Among the ubiquitinated peptides recovered from RIPK1, one, EubKVYQMLQK, appeared exclusively when HERC4 was present and was absent with a catalytically inactive HERC4 mutant. The fragmentation spectrum unmasked lysine 627 on human RIPK1 as the ubiquitination site, a residue within the death domain that is highly conserved across species and corresponds to K612 in the mouse protein. This was a striking finding, because earlier work had shown that substituting this very lysine prevents TNF-induced cell death, hinting that ubiquitination there might be a necessary licensing step. A catalytically inactive HERC4 mutant, engineered on the basis of AlphaFold3 predictions by mutating H1023, C1025 and D1030, still bound RIPK1 but could no longer ubiquitinate it, and cells expressing this mutant were markedly resistant to necroptosis, proving that the ligase activity itself is what matters.

The mechanism that emerges is elegant and precise. HERC4 does not act indiscriminately: its interaction with RIPK1 occurs only under apoptotic or necroptotic stimulation, not with TNF alone, and is abolished by the RIPK1 kinase inhibitor necrostatin 1s. The team showed that HERC4 selectively recognizes RIPK1 that has been autophosphorylated at serine 166, the hallmark of RIPK1 kinase activation, since an S166A mutant lost the interaction while phosphomimetic S166D and S166E variants enhanced it. Sequential immunoprecipitation of the TNFR1 signaling complexes revealed that HERC4 is absent from membrane-bound complex I and instead binds complex I-derived, S166-phosphorylated RIPK1 once it has been released into the cytosol. There, HERC4’s K63-linked ubiquitination of the death domain enables RIPK1 to oligomerize, both with itself and with FADD, nucleating the assembly of complex IIa and, when caspases are blocked, the RIPK1–RIPK3 necrosome. Gel-filtration analysis confirmed that intact HERC4, but not the catalytic mutant, permits the formation of high-molecular-weight complexes containing phosphorylated RIPK1, RIPK3, MLKL and caspase 8.

Importantly, HERC4’s role is confined to the death arm of TNF signaling. The enzyme is dispensable for NF-κB activation: HERC4 knockout left phosphorylation of P65, IκBα, TAK1 and IKKα/β untouched, and it did not alter RIPK1 ubiquitination at K377, the cIAP1/2-mediated modification in complex I that supports survival signaling. This separation is what makes HERC4 so attractive as a drug target. Blocking it would, in principle, disarm TNF’s lethal potential while leaving its beneficial inflammatory and prosurvival functions intact, an effect similar to direct RIPK1 kinase inhibition but achieved one step upstream, at the licensing event itself.

The in vivo evidence is compelling. Mice lacking HERC4 were born and bred normally, indicating the protein is not essential for development. But when challenged with an overdose of TNF, a model of systemic inflammatory response syndrome, all wild-type littermates succumbed within 28 hours, whereas 80 percent of HERC4-deficient mice survived. The protected animals showed lower serum IL-6, reduced caspase 3 and PARP cleavage in the intestine, less cecal tissue damage on histology, and markedly reduced RIPK1 autophosphorylation. In a second model of acute liver injury induced by TNF and D-galactosamine, nearly all wild-type mice reached humane endpoints within four to six hours, while more than 70 percent of HERC4-deficient mice survived, with lower ALT and AST liver enzymes, reduced IL-6, suppressed hepatic caspase 3 activation and diminished histological damage.

The discovery resolves a long-standing conundrum in cell death biology: why RIPK1’s kinase activity, whose only known substrate is RIPK1 itself, is essential for TNF-induced death. The answer is that autophosphorylation at S166 creates the molecular tag that HERC4 recognizes, and HERC4’s ubiquitination of the death domain is what converts the phosphorylated kinase into a competent nucleator of the death complexes. Beyond inflammatory diseases such as SIRS, colitis and liver injury, the finding may reach into oncology, where necroptosis’s immunogenic nature has been proposed as a way to stimulate antitumor immunity, and where HERC4 has previously been implicated as a tumor suppressor. By supplying RIPK1 with what the authors call its license to kill, HERC4 now stands as both a mechanistic keystone of TNF signaling and a promising target for diseases driven by aberrant cell death.

Subject of Research: HERC4-mediated ubiquitination of RIPK1 as the molecular switch initiating TNF-induced cell death and inflammation

Article Title: HERC4-mediated ubiquitination licenses RIPK1 to initiate TNF-induced cell death

Article References: Lu, H., Du, T., Li, L., Cao, D., Li, K., Liu, L., Li, R., Yu, X., Hou, S., Wang, X., Shi, M., Liu, Y., Ma, F., Chen, S., Walczak, H., & He, S. (2026). HERC4-mediated ubiquitination licenses RIPK1 to initiate TNF-induced cell death. Nature Structural & Molecular Biology. https://doi.org/10.1038/s41594-026-01871-y

Image Credits: AI Generated

DOI: 10.1038/s41594-026-01871-y

Keywords: HERC4, RIPK1, TNF, ubiquitination, necroptosis, apoptosis, RIPK3, MLKL, inflammation, E3 ligase, liver injury, cell death signaling

Biologists have spent decades mapping how cells police their proteins. Chaperones refold misfolded chains, the proteasome shreds irreparable ones, and autophagy devours bulky aggregates. DNA repair pathways similarly guard the genome. But glycogen, a polymer of glucose assembled by glycogen synthase and sculpted by branching enzyme, has lacked an obvious surveillance mechanism. That gap matters clinically. In adults, aberrant, poorly branched glycogen builds up as polyglucosan bodies in disorders such as adult polyglucosan body disease, a condition caused by mutations in the branching enzyme gene GBE1 that can produce progressive weakness, numbness and neurogenic bladder. Until now, no one had identified a cellular machine that actively detects and removes these defective polymers before they crystallize into disease.

The Cambridge team began with genetics. Mice engineered to lack the ligase activity of RNF213, an enormous E3 ubiquitin ligase previously implicated in Moyamoya disease, a rare cerebrovascular disorder, accumulated polyglucosan in specific brain regions: the cerebellum, the pons and the hippocampus. That pattern of accumulation pointed to a protective role in astrocytes, the star-shaped support cells that stockpile much of the brain’s glycogen. The inference was striking. If removing RNF213’s enzymatic activity caused polyglucosan to pile up, then RNF213’s normal job might be to recognize aberrant glycogen and mark it for destruction, much as E3 ligases mark damaged proteins.

To test that idea directly, the researchers built a cell-based system in which cells manufacture polyglucosan, the pathological, sparsely branched form of glycogen. In these cells, RNF213 selectively attached ubiquitin to the abnormal polymer while leaving healthy, well-branched glycogen untouched. That selectivity is the crux of the discovery. Quality control is only useful if it distinguishes good from bad, and here the enzyme appeared to do exactly that, reading the structural state of a carbohydrate granule and tagging only the defective version. The tagged polyglucosan was then engulfed by autophagosomes, the cell’s membrane-bound disposal vesicles, in a process the authors describe as autophagy of ubiquitylated aberrant glycogen.

How does a protein enzyme read the architecture of a sugar polymer? Cryo-electron microscopy provided the answer. Wanda Kukulski’s group at the University of Bern joined the effort to solve the structure of RNF213 bound to maltoheptaose, a linear seven-glucose fragment derived from glycogen. The images revealed that RNF213 carries a carbohydrate-binding module, CBM20, that grips linear oligosaccharides. This detail matters because normal glycogen is densely branched, studded with short side chains, whereas polyglucosan is comparatively linear and sparse. The CBM20 domain, the structure implies, acts as a molecular ruler that prefers the exposed linear stretches characteristic of aberrant glycogen.

The structural work also explained a paradox. When the researchers mutated the carbohydrate-binding surface of CBM20, RNF213 did not lose its activity; it gained it, promiscuously ubiquitylating even physiological glycogen. In other words, the binding domain normally restrains the enzyme, preventing it from attacking healthy glycogen and licensing activity only when the polymer presents the right structural cues. Disrupting that restraint converts a precise quality control factor into a blunt instrument. This regulatory logic, in which substrate recognition gates catalytic output, echoes themes from protein quality control but is here applied to a branched carbohydrate, a conceptual first.

Ubiquitylation is only the first step of disposal. The study traced what happens next through epistasis analysis, which places genes in a pathway by testing how mutations combine. RNF213 acts upstream of LUBAC, a linear ubiquitin chain assembly complex, suggesting a hierarchy in which one E3 ligase initiates tagging and a second elaborates the mark. The resulting ubiquitin coat on polyglucosan then recruits autophagy receptors, including SQSTM1, also known as p62, TAX1BP1 and optineurin. These adaptor proteins physically link the tagged cargo to the autophagy machinery, triggering uptake into autophagosomes and eventual degradation. The network implies that glycogen surveillance, like protein surveillance, is a multi-layered system with division of labor among several enzymes.

The discovery also reframes RNF213 itself. The gene has attracted intense clinical interest because loss-of-function variants cause Moyamoya disease, and the protein’s ligase activity has been linked to lipid droplet biology and innate immunity. Adding glycogen quality control to its portfolio suggests that RNF213 is a broad-spectrum surveyor of cytoplasmic polymers, and it raises the question of whether some Moyamoya pathology might involve glycogen mishandling in brain cells, a possibility the study does not directly establish but which now invites investigation. It also broadens the emerging concept of non-protein ubiquitylation, in which ubiquitin marks lipids and carbohydrates, into a central pillar of cellular housekeeping.

For medicine, the implications are tantalizing but early. Adult polyglucosan body disease and related glycogen storage disorders currently lack therapies that address the root problem of insoluble polymer accumulation. If the RNF213 pathway can be understood well enough to enhance, perhaps by stabilizing the enzyme’s activity or boosting the autophagy receptors it engages, cells might in principle be taught to clear polyglucosan before it accumulates. The mouse data showing region-specific polyglucosan buildup in the absence of RNF213 ligase activity provide a model for testing such strategies. Caution is warranted: the work identifies a mechanism, not a treatment, and translating ubiquitin biology into drugs has historically proven difficult.

Scientifically, the study’s deepest significance may be conceptual. Quality control, biologists now realize, is not a protein-only affair. DNA, RNA, lipids and now glycogen all fall under the ubiquitin system’s jurisdiction, each with dedicated sensors and disposal routes. The Cambridge and Bern teams have shown that even a humble energy store is inspected, tagged and recycled with the same molecular rigor applied to a misfolded enzyme. Cells, it turns out, do not merely fill their glycogen granules and forget them. They watch them, and when the branching goes wrong, they call in RNF213.

Subject of Research: Ubiquitin-dependent quality control of glycogen by the E3 ligase RNF213

Article Title: Quality control of glycogen through direct ubiquitylation by RNF213

Article References: Yip, M. C. J., Naydenova, K., Otten, E. G., Heatley, A., Moe, A., Anton, L., de los Reyes-Ramírez, L., Jolin, H. E., Langevin, F., Wiacek, M., Franco, C., Bertolotti, A., Kukulski, W., McKenzie, A. N. J., & Randow, F. (2026). Quality control of glycogen through direct ubiquitylation by RNF213. Nature. https://doi.org/10.1038/s41586-026-11139-6

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11139-6

Keywords: glycogen, RNF213, ubiquitylation, autophagy, polyglucosan, E3 ligase, cryo-EM, CBM20, astrocytes, neurodegeneration, LUBAC, SQSTM1

The fundamental insight behind PROTACs is deceptively simple: instead of blocking a disease-causing protein, destroy it outright. Classical small-molecule drugs operate through what pharmacologists call occupancy-driven inhibition, meaning they must remain bound to their target to exert effect. This strategy struggles against proteins that lack a well-defined binding pocket, even when those proteins are powerful drivers of disease. PROTACs sidestep the problem entirely by hijacking the ubiquitin-proteasome system, the cell’s own garbage disposal machinery. These heterobifunctional molecules carry two business ends, one ligand that grips the target protein and another that recruits an E3 ubiquitin ligase, connected by a chemical linker. When the chimera brings both proteins into proximity, the ligase tags the target with chains of ubiquitin, the universal molecular death mark, and the 26S proteasome chews the protein into peptides.

The mechanistic details matter enormously for drug design. The human genome encodes roughly two E1 ubiquitin-activating enzymes, about forty E2 conjugating enzymes, and more than six hundred E3 ligases, offering enormous untapped selectivity potential. Crucially, PROTAC action is catalytic rather than stoichiometric: a single degrader molecule can, in principle, drive the elimination of many copies of its target, dissociating after each degradation cycle to find another. But productive destruction depends on forming a stable three-body complex between target, degrader, and ligase, a property known as ternary complex cooperativity. Studies of the BRD4 degrader MZ1 using surface plasmon resonance and crystallography have shown that longer ternary complex residence time correlates with more efficient ubiquitination, and that high cooperativity allows MZ1 to selectively degrade BRD4 while sparing its close relatives BRD2 and BRD3. There is also a pharmacological quirk that developers must respect: at high concentrations, PROTACs can saturate either protein separately, collapsing ternary complex formation and paradoxically reducing degradation. This bell-shaped dose-response behavior, known as the hook effect, complicates dose selection in ways conventional inhibitors never face.

The design of these molecules is a delicate balancing act across three structural elements. Target ligands need not maximize binding affinity, since moderate affinity often suffices when the ternary complex is cooperative and geometrically productive, but they must tolerate the added bulk of a linker without losing selectivity. On the ligase side, cereblon, or CRBN, and von Hippel-Lindau, or VHL, dominate the field because high-quality ligands exist for both. CRBN recruiters derived from thalidomide, lenalidomide, and pomalidomide benefit from a favorable medicinal chemistry profile, while VHL ligands built around a stereochemically defined hydroxyproline core, exemplified by the nanomolar-affinity probe VH298, often deliver stable ternary complexes with fewer off-target effects on natural cereblon substrates. Emerging ligases including KEAP1, RNF114, and DCAF family proteins may eventually enable tissue-selective degradation, though most remain hampered by limited ligand availability and incomplete structural characterization. Linker engineering ties everything together: too short and the complex is strangled, too long and entropy penalties mount, and subtle modifications such as methyl substitution have been shown to improve oral absorption while preserving degradation efficiency.

Nowhere is the platform’s promise more visible than in oncology, where cancer cells’ dependence on a handful of overexpressed or mutant proteins makes them ideal targets for elimination. ARV-110, also known as bavdegalutamide, is an orally bioavailable androgen receptor degrader designed for metastatic castration-resistant prostate cancer patients who have stopped responding to conventional antagonists like enzalutamide. Early phase 1/2 data revealed encouraging activity in a molecularly defined subgroup: patients whose tumors carried AR mutations T878 or H875 showed a prostate-specific antigen fifty percent response rate of approximately forty-six percent. Yet the drug’s limitations are instructive, since it fails to degrade the common resistance variant AR-V7 or the L702H mutation, and gastrointestinal side effects such as nausea and diarrhea have accompanied its use. The lesson, the review emphasizes, is that clinical efficacy depends not only on degradation itself but on biomarker-guided patient selection rooted in the molecular subtype of each tumor.

On the breast cancer front, ARV-471, known as vepdegestrant, has advanced furthest of all PROTACs. Developed for ER-positive, HER2-negative advanced breast cancer, the molecule eliminates both wild-type and mutated estrogen receptors, including the notoriously difficult ESR1 mutations that drive endocrine resistance. Preclinical studies showed deeper ER knockdown than fulvestrant, the traditional selective estrogen receptor degrader, and clinical phase 1/2 results demonstrated robust activity with a manageable safety profile in heavily pretreated patients. Researchers identified 200 milligrams once daily as the optimal dose for balancing efficacy and tolerability, and the compound is now being evaluated in the global phase 3 VERITAC-2 trial, a milestone marking one of the first PROTACs to reach late-stage development for solid tumors. Published results in the New England Journal of Medicine have confirmed the approach’s clinical credibility.

Blood cancers have yielded another compelling success story. Bruton’s tyrosine kinase inhibitors such as ibrutinib frequently lose effectiveness when tumors acquire the C481 mutation, which prevents covalent binding to the kinase’s active site. BTK degraders work where inhibition fails because they do not depend on sustained occupancy of any single pocket; they remove the entire protein, abolishing both enzymatic activity and the oncogenic scaffolding functions that can persist even when the kinase is silenced. NX-2127, an oral cereblon-recruiting degrader, eliminates wild-type and C481-mutant BTK alike, and uniquely also degrades the immunomodulatory transcription factors IKZF1 and IKZF3, potentially amplifying anti-tumor efficacy through T-cell activation. Whether this dual action translates into durable benefit without excessive immunological toxicity remains an open question that ongoing trials must answer.

Beyond cancer, the review surveys emerging frontiers that could dramatically widen the platform’s reach. Neurodegenerative diseases are particularly attractive because they are driven by toxic, aggregation-prone proteins such as tau that may be better addressed by removal than inhibition, although the blood-brain barrier imposes punishing constraints on molecular size, polarity, and efflux susceptibility. Recent work with neurotransmitter-derived lipidoid nanoparticles carrying tau-targeting PROTAC-DNA nanocomplexes has promoted tau clearance and cognitive recovery in disease models. In immunology, degraders of IRAK4 and STAT family proteins promise cleaner modulation of inflammatory signaling than reversible inhibitors, and early clinical candidates such as KT-474 are already in testing. Meanwhile, photoactivatable PROTACs offer spatial and temporal control over degradation, antibody-directed delivery systems could solve tissue penetration problems, and macrocyclic degrader designs are shrinking the molecules’ daunting physicochemical footprint.

Substantial obstacles remain before targeted protein degradation can fulfill its promise. Most clinically investigated PROTACs occupy beyond-rule-of-five chemical space with molecular weights between roughly 700 and 1200 daltons, creating persistent difficulties with solubility, passive permeability, metabolic stability, and oral bioavailability. Resistance mechanisms are already appearing, including altered E3 ligase expression, impaired proteasome function, target protein mutations, and compensatory signaling pathways, prompting development of ligase-switching strategies, dual-target degraders, and rational combinations. Manufacturing is its own headache, since assembling two pharmacophores through a linker while preserving stereochemical purity complicates scale-up and inflates costs, argues for early integration of process chemistry and Quality-by-Design principles. Formulation science, from cyclodextrins to lipid nanoparticles and solid dispersions, is being marshaled to rescue otherwise marginal candidates. Artificial intelligence and machine learning are increasingly deployed for ternary complex prediction and linker selection, though docking scores alone cannot yet reliably forecast degradation efficiency and must be validated against biophysical measurements.

The overarching conclusion of the review is that PROTACs now constitute a genuinely distinct pharmacological modality whose success demands simultaneous optimization of ternary complex cooperativity, degrader pharmacokinetics, and tissue-selective ligase recruitment, rather than simple pursuit of binding affinity. The strongest clinical evidence remains concentrated in hormone-driven cancers, but the conceptual reach of the platform extends to proteins that traditional drugs simply could not touch. If the field can deliver ligandable E3 ligases beyond cereblon and VHL, predictable degradation through computational design, orally bioavailable degraders, and validated pharmacodynamic biomarkers that track target loss directly, targeted protein degradation may graduate from elegant chemical biology tool to a foundational pillar of twenty-first-century medicine.

Subject of Research: PROTAC-mediated targeted protein degradation for drug discovery and clinical development

Article Title: Proteolysis targeting chimeras for drug discovery from mechanistic basis to clinical translation

Article References: Proteolysis targeting chimeras for drug discovery from mechanistic basis to clinical translation. (n.d.). https://doi.org/10.1007/s44371-026-00963-4

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00963-4

Keywords: PROTACs, targeted protein degradation, ubiquitin-proteasome system, E3 ligase, medicinal chemistry, bavdegalutamide, vepdegestrant, NX-2127, ternary complex cooperativity, hook effect, oncology drug development, beyond-rule-of-five